Pharmaceutical-Grade Cannabidiol Shows Promising Cardiac Safety Profile in High-Risk Patients

A pharmaceutically manufactured cannabidiol查看药品详情 (CBD) formulation has demonstrated a favorable cardiac safety profile in patients with cardiovascular risk factors, according to research presented at the European Society of Cardiology查看公司主页's Heart Failure (搜索)搜索该疾病 2025 congress in Belgrade, Serbia.

The study comes at a critical time when treatment options for inflammatory heart conditions such as myocarditis (搜索)搜索该疾病 and pericarditis (搜索)搜索该疾病 remain limited. Cannabidiol查看药品详情, which lacks the psychotropic effects of cannabis, has shown promise in preclinical studies by inhibiting the inflammasome pathway (搜索)搜索该靶点—a key cellular process involved in cardiac inflammation.

"We knew that patients with cardiovascular disease or risk factors who were hospitalized for COVID-19 (搜索)搜索该疾病 infection may be at high risk of cardiac inflammation," explained Dr. Leslie Cooper, Co-Principal Investigator from the Mayo Clinic查看公司主页 in Jacksonville, Florida. "We conducted a placebo-controlled trial of an oral pharmaceutically manufactured cannabidiol查看药品详情 formulation to assess its efficacy and safety."

Trial Design and Patient Population

The prospective, randomized, placebo-controlled trial enrolled adult patients with either established cardiovascular disease or at least one major cardiovascular risk factor who had been hospitalized for non-critical COVID-19 (搜索)搜索该疾病 infection. Participants received either Good Manufacturing Practice (GMP)-cannabidiol查看药品详情 titrated up to 7.5 mg/kg twice daily (or maximum tolerated dose) or placebo.

Although the trial was terminated early due to declining COVID-19 (搜索)搜索该疾病 cases, the safety analysis included 89 patients with a mean age of 61 years, with 43% being female. Of these, 45 patients received GMP-cannabidiol查看药品详情 and 44 received placebo.

Safety Outcomes Show Comparable Profiles

The primary safety endpoint examined serious adverse events (SAEs) and adverse events (AEs) during the 60 days following randomization. Results showed similar safety profiles between the treatment groups:

• Treatment-related adverse events: 24.4% with GMP-cannabidiol vs. 22.7% with placebo
• Serious adverse events: 11.1% with GMP-cannabidiol vs. 9.1% with placebo
• No deaths occurred in the GMP-cannabidiol group, while two deaths due to respiratory failure were reported in the placebo group

Common adverse events were distributed similarly between groups:

• Gastrointestinal disorders: 22.2% with GMP-cannabidiol vs. 20.5% with placebo
• Nervous system disorders: 17.8% with GMP-cannabidiol vs. 18.2% with placebo
• Respiratory, thoracic, and mediastinal disorders: 11.1% with GMP-cannabidiol vs. 9.1% with placebo

Cardiac Safety Findings

Particularly noteworthy were the cardiovascular safety findings, a critical consideration for any therapy targeting cardiac conditions. Cardiac disorders were reported in exactly 9% of patients in both the GMP-cannabidiol查看药品详情 and placebo groups.

Only one patient (2%) in the GMP-cannabidiol查看药品详情 group developed mild QTc prolongation detected by electrocardiogram (ECG). Overall, changes in ECG measurements were minimal, with similar mean QTc values from baseline to day 28 in the GMP-cannabidiol group (425 msec and 418 msec, respectively) and in the placebo group (418 msec and 419 msec, respectively).

Implications for Future Research

"GMP-cannabidiol查看药品详情 was well tolerated overall and most importantly, the rate of cardiac side effects was low and similar compared with placebo," Dr. Cooper summarized. "These safety data are encouraging as two larger trials assessing efficacy and safety are underway with GMP-cannabidiol."

The phase II ARCHER trial investigating cannabidiol查看药品详情 in patients with acute myocarditis (搜索)搜索该疾病 is expected to report results later in 2025, while findings from the phase III MAVERIC trial in patients with recurrent pericarditis (搜索)搜索该疾病 are anticipated in 2026.

Cannabidiol's Potential Mechanism in Cardiac Inflammation

Cannabidiol查看药品详情 has gained scientific interest for its immunomodulatory properties without the psychotropic effects that complicate the use of other cannabis-derived compounds. Its mechanism appears to involve attenuating inflammasome activation, a process linked to maladaptive cardiac inflammation and fibrosis that contributes to heart failure (搜索)搜索该疾病 progression.

The inflammasome pathway (搜索)搜索该靶点 has been identified as a key driver in the development and progression of myocarditis (搜索)搜索该疾病, pericarditis (搜索)搜索该疾病, and heart failure (搜索)搜索该疾病. By targeting this pathway, cannabidiol查看药品详情 may offer a novel approach to managing inflammatory heart conditions that currently have few effective treatment options.

Significance in Post-Pandemic Cardiology

The study's context within the COVID-19 (搜索)搜索该疾病 pandemic highlights the complexity and unmet needs in treating cardiac complications arising from viral infections. The observed safety in this vulnerable patient population offers hope for addressing myocarditis (搜索)搜索该疾病 and pericarditis (搜索)搜索该疾病 following infectious triggers, a scenario that has become increasingly relevant in post-pandemic clinical care.

While the trial was unable to fully assess efficacy due to early termination, the favorable safety profile provides a foundation for ongoing and future studies. If proven effective in larger trials, pharmaceutical-grade cannabidiol查看药品详情 could potentially revolutionize treatment approaches for inflammatory cardiac conditions, offering a new option for patients with limited therapeutic alternatives.

As the medical community awaits results from the ARCHER and MAVERIC trials, this safety study represents an important step forward in exploring cannabidiol查看药品详情's potential role in cardiovascular medicine.